GHK-Cu vs Matrixyl: Which Skin Peptide Has Better Evidence?
Published by AmpleLab Research
Matrixyl is one of the most recognisable names on a peptide serum label, and GHK-Cu is the copper peptide that keeps turning up beside it in threads asking which to use. Those threads usually settle the question with confidence in one direction or the other. The papers behind both peptides are more interesting, and more modest, than either camp suggests.
This article compares what each peptide is, how it is meant to work, and what the human trials show, including who ran them. AmpleLab sells a GHK-Cu serum and does not sell a Matrixyl product, so we have a stake in this comparison; the evidence is laid out so you can check it for yourself.
First, Which Matrixyl?
Matrixyl is a brand name, not a single molecule. The original is palmitoyl pentapeptide-4 (Pal-KTTKS): five amino acids with a fatty-acid palmitoyl tail attached. Matrixyl 3000 is a different blend, made from palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, according to a 2017 review of topical peptides. The ingredient list shows which one a product contains.
One detail catches people out. Palmitoyl tripeptide-1 is the same three amino acids as GHK, with a fatty acid attached and no copper. It is not a copper peptide, and it is not interchangeable with GHK-Cu.
GHK-Cu
INCI name: Copper Tripeptide-1. A copper complex of the tripeptide GHK.
Matrixyl (original)
INCI name: Palmitoyl Pentapeptide-4. The KTTKS pentapeptide with a palmitoyl tail.
Matrixyl 3000
INCI names: Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7. A two-peptide blend; the tripeptide is GHK without copper.
Brand names and blends change, so the INCI list is the reliable guide to what is in a bottle.
Two Peptides, Two Theories
Both peptides are discussed in the context of collagen and extracellular-matrix remodelling, but the proposed mechanisms and the supporting evidence differ. Laboratory findings give a rationale for using them in skincare; they do not, by themselves, show how much either ingredient improves skin when applied in a finished serum.
GHK is a three-amino-acid peptide that binds copper. A 2017 review describes it as acting as both a signal and a carrier peptide: the peptide holds the copper in a form that can interact with cells, and the research describes effects on collagen, matrix-remodelling enzymes and gene expression in cell and wound models. Our guides to its antioxidant mechanism and the 4,000 genes claim cover what is and is not established. Ex vivo work by Hostynek and colleagues found copper from GHK-Cu moved through dermatomed human skin ex vivo. That supports dermal delivery, but it does not show how much intact peptide reaches living skin structures after normal use, or whether it produces a visible benefit.
KTTKS is a five-amino-acid sequence from type I procollagen. In cell studies it stimulates fibroblasts to make more collagen types I and III and fibronectin, which is the basis for the idea that it signals skin to build more matrix. The palmitoyl tail is a fatty acid added to help the peptide into skin. A 2011 review of topical KTTKS found a sound in vitro basis for its action on fibroblasts, while noting a lack of skin-penetration data and relatively few clinical studies.
Size is part of the delivery question. A long-quoted rule says peptides above about 500 Da cannot cross the skin barrier, although the 2017 review notes that newer work challenges it. GHK-Cu is roughly 400 Da and Pal-KTTKS roughly 800 Da. Neither number settles delivery on its own.
What the Human Trials Show
Here is what the human evidence looks like for each, starting with the best-known published Matrixyl trial.
A 12-week, double-blind, placebo-controlled, split-face trial in 93 women aged 35 to 55, comparing a moisturiser with and without 3 ppm of Pal-KTTKS. Wrinkles and fine lines were reduced on instrumental image analysis and expert grading, and the peptide was well tolerated. The first author was at Procter & Gamble. It tested a single formula over three months, so it supports that peptide in that formula, not every product that uses the name.
The GHK-Cu human studies are smaller. A pilot in 20 volunteers compared copper peptide, vitamin C and tretinoin on thigh skin biopsies, and our research history covers the rest. One controlled facial trial of GHK-Cu is below, and it is not a flattering result.
A randomised study in patients who had circumoral CO2 laser resurfacing, comparing post-treatment skin care with and without GHK-Cu. Thirteen patients completed it. Erythema recovery and objective improvement in wrinkles and skin quality did not differ between groups, although the GHK-Cu group rated its overall skin quality higher (P = .04). It is small and set in post-procedure skin, so it does not describe everyday use, and it did not compare GHK-Cu with another peptide.
Broader reviews describe the same pattern for both. The 2017 review of topical peptides lists several GHK-Cu studies: the 20-volunteer pilot, two 12-week studies in 71 and 41 women reported as a conference abstract, and a 67-woman biopsy study. For Pal-KTTKS it lists results taken from a patent and a trade-press article alongside the published trial. Its overall conclusion is that peptide efficacy studies are not frequently published in scientific journals, and that in some trials the effect cannot be attributed to one peptide because other actives were in the formula.
A review of topical anti-ageing peptides. It sorts them into signal, carrier, neurotransmitter-inhibitor and enzyme-inhibitor groups, with GHK-Cu described as acting as both signal and carrier peptide. It notes little in vivo efficacy data for many peptides, very small participant numbers in some studies, and that observed results cannot always be credited to the named peptide.
Matrixyl 3000 has supplier-reported figures of its own, circulated through the trade press rather than as a journal paper with full methods. One trade report describes 48 men applying it at 4% for two months, with the mean depth of the main wrinkle down 10.2% and its volume down 17.1%; the article does not say who ran the study. Accounts of the supplier's studies are not consistent on details such as test concentration and group size, which is a reason to treat those numbers as supplier claims until they are published with full methods.
The newest overview points the same way. A 2026 systematic review of randomised trials of peptides for skin ageing found 19 trials with 1,341 participants. Seventeen tested oral peptides, many of them collagen peptides, and only two tested topical ones. Its pooled wrinkle result was modest, heterogeneity was extremely high, and the authors called for larger trials with standardised outcomes. That makes it useful context for the wider field rather than direct evidence for either peptide here, and it shows how thin the topical randomised evidence is.
Who Paid for the Evidence
Cosmetic trials are often paid for by the companies that sell the ingredient. That is understandable and not a flaw in itself, but it makes the funder worth knowing for both peptides.
For Pal-KTTKS, the 93-woman journal paper has a first author who worked at Procter & Gamble. Separately, a 2005 conference abstract by company authors on a pentapeptide moisturiser states that the work was fully supported by Procter & Gamble. The Matrixyl 3000 figures we found are attributed to its supplier.
GHK-Cu has its own commercial history. Its discoverer co-founded ProCyte to commercialise copper peptides, and the patent on cosmetic uses expired in 2004, as our research history describes. Some of its larger human studies were presented at meetings rather than published in full. The Miller trial above was a small randomised study from a facial plastic surgery group.
Choosing Without a Clear Winner
On the evidence we could verify, there is no winner, and the choice depends on what you want from a serum.
If the question is facial wrinkles and the evidence you want is a full published trial, Pal-KTTKS has one, with the caveats above. If the interest is the copper-peptide research record, including wound healing and tissue remodelling, GHK-Cu has the longer history, and our GHK-Cu versus retinol article covers how it compares with an active that has far larger trials. Our 1% GHK-Cu Face and Skin Serum page has the formulation.
We found no head-to-head trial and no combination trial for the two. Any advice on layering them is reasoning rather than evidence, and if you try both, introducing them one at a time keeps the result readable.
Whichever you choose, check the numbers on the label. A percentage of a branded blend and a percentage of a pure peptide are different measures: the Procter & Gamble trial used 3 ppm of pure Pal-KTTKS, which is 0.0003%, while the trade report above quotes 4% of a branded ingredient. Our guides to reading concentration on copper peptide labels and to what separates a transparent GHK-Cu formula from a marketing claim explain how to read them, including why independent batch testing matters. AmpleLab publishes the independent HPLC report for its GHK-Cu batch on our lab testing page; it covers the raw peptide, not the finished serum.
Frequently Asked Questions
Is Matrixyl better than GHK-Cu?
The evidence does not show that either is better. Matrixyl's original peptide, Pal-KTTKS, has a published 93-woman double-blind trial led by a Procter & Gamble researcher. GHK-Cu has a longer research history but smaller human studies, including a small randomised trial, in which 13 patients completed treatment, that found no added objective benefit after laser resurfacing. We found no head-to-head trial and no large independent trial of either.
Are Matrixyl and GHK-Cu the same thing?
No. GHK-Cu is a copper complex of the tripeptide GHK, listed as Copper Tripeptide-1. Original Matrixyl is palmitoyl pentapeptide-4, a different five-amino-acid peptide. Matrixyl 3000 contains palmitoyl tripeptide-1, which is GHK with a fatty acid attached and no copper, plus palmitoyl tetrapeptide-7.
Which has more clinical evidence?
Pal-KTTKS has a full published double-blind trial in 93 women. GHK-Cu has several smaller human studies, some reported as conference abstracts, and a longer record in wound-healing research. Neither has large independent trials that we could find, and a 2026 review of randomised peptide trials for skin ageing found only two topical ones among 19.
Can I use GHK-Cu and Matrixyl together?
We found no trial testing them together or against each other, so there is no evidence to say whether combining them helps. If you want to try both, start one at a time and give each several weeks, so you can tell which is helping or irritating.
Are both safe?
The Cosmetic Ingredient Review panel assessed Copper Tripeptide-1 together with palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, the two peptides in Matrixyl 3000, in one 2018 report and concluded they are safe in cosmetics as used. The 93-woman Pal-KTTKS trial reported the peptide was well tolerated. Safe as used applies to the concentrations and practices reviewed, and individual skin can still react.
Do the percentages on peptide serums compare directly?
No. A percentage of a branded blend and a percentage of a pure peptide measure different things. The main Pal-KTTKS trial used 3 ppm of pure peptide, which is 0.0003%, while a trade report on Matrixyl 3000 quotes 4% of the branded ingredient. The 3 ppm is simply the amount in the tested moisturiser; it is not a recommended concentration or a measure of efficacy against GHK-Cu. Comparing label percentages across different peptides says little about how much active reaches the skin.
Selected Research
This article is provided for educational purposes and does not constitute medical advice. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.